Case Report

Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody

Yusho Ishii,1 Hiroshi Fujii,1 Koichiro Sugimura,2 Tsuyoshi Shirai,1 Yosuke Hoshi,1 Yoko Fujita,1 Yuko Shirota,1 Tomonori Ishii,3 Hiroaki Shimokawa,2 and Hideo Harigae1

1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Japan
2Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Japan
3Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Miyagi, Japan

Correspondence should be addressed to Hiroshi Fujii; hfujii@med.tohoku.ac.jp

Received 25 October 2019; Revised 26 January 2020; Accepted 31 January 2020; Published 26 February 2020

Academic Editor: Mario Salazar-Paramo

Copyright © 2020 Yusho Ishii et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Systemic sclerosis (SSc) is characterized by skin sclerosis and multiple organ damages which may cause mortality and is usually accompanied with several specific autoantibodies, each of which is associated with characteristic complications. Among them, anticentriole antibody is recently reported to be highly associated with SSc-associated pulmonary arterial hypertension (SSc-PAH). In general, several vasodilators are used as therapeutic drugs for SSc-PAH, whereas immunosuppressive therapies are not. Here, we report the case of a 62-year-old female with anticentriole antibody-positive SSc-PAH treated with immunosuppressants and vasodilators. She presented with two-year exertional dyspnea and was diagnosed with PAH and SSc owing to the centriole staining pattern and other symptoms without digital sclerosis. Oral vasodilators were initially administered but were not sufficiently effective on dyspnea. Immunosuppressants such as prednisolone and cyclophosphamide were started. Both of them improved mean pulmonary arterial pressure and 6-minute walk distance, and the anticentriole antibody also disappeared. In this case, SSc-PAH with anticentriole antibody was properly diagnosed and immunosuppressants and vasodilators improved the hemodynamics of PAH with anticentriole antibody and stably maintained it and, in addition, reduced the titer of anticentriole antibody. This indicates that anticentriole antibody might represent a good responsive group to therapies among subgroups of patients with SSc-PAH.

1. Introduction

Systemic sclerosis (SSc) is a systemic autoimmune disease and presents with vasculopathy, inflammation, and fibrosis of the skin and internal organs [1, 2]. SSc also presents with heterogeneous organ damages such as pulmonary arterial hypertension (PAH) and interstitial pneumonias (IP), gastrointestinal dysfunction, cardiac dysfunction, and skin disorder [1, 2]. PAH is one of the serious complications that induce high mortality. Generally, the recommended treatments for SSc-PAH comprise vasodilators, including phosphodiesterase-5 inhibitor (PDE5i), endothelin receptor antagonist, prostacyclin analogs, and soluble guanylate cyclase stimulator [3], which repress the rapid progression of SSc-PAH [4]. Although immunosuppressive therapies are not generally effective for SSc-PAH compared with other connective tissue diseases associated with PAH [2, 5], clinical trials for rituximab, tocilizumab, and dimethyl fumarate for SSc-PAH are underway and are effective in some cases of SSc-PAH [6–9]. Some case reports have indicated that a subpopulation of patients with SSc-PAH is responsive to immunosuppressive therapy [10, 11]; however, it still remains unclear what kind of clinical features or biomarkers are useful to identify SSc-PAH patients on whom immunosuppressive therapies are effective.

Patients with SSc show various types of autoantibodies, and each autoantibody is associated with characteristic clinical phenotypes such as anti-topoisomerase I (diffuse sclerosis, IP, digital ulcer (DU), and severe heart disease), anti-centromere (limited sclerosis, DU, calcinosis, and...
PAH), anti-RNA polymerase III (diffuse sclerosis and renal crisis), anti-U3 RNP (diffuse sclerosis, PAH, IP, severe heart disease, myositis, and overlap syndrome), anti-Th/To (limited sclerosis, PAH, and IP), anti-PM-Scl (limited sclerosis and SSc-myositis overlap syndrome), and anti-Ku antibodies (overlap syndrome and myositis) [12–14]. In addition, the anticentriole antibody is recently reported to be highly associated with PAH in patients with SSc [15]. Here, we present the case of a patient with SSc-PAH with anticentriole antibody who was successfully treated with vasodilators and immunosuppressive therapies. The presence of the anticentriole antibody is rare; however, it may be a useful biomarker that affects diagnostic and therapeutic strategies for SSc-PAH.

2. Case Presentation

A 62-year-old female presented with two-year exertional dyspnea. Her dyspnea progressively worsened and severe pitting edema of the lower extremities appeared, so she visited her previous doctor and took an electrocardiography which revealed right heart overload. Blood examination showed that the value of brain natriuretic peptide (BNP) was 537 pg/ml. Echocardiography revealed that the ejection fraction was 78.7%. Tricuspid regurgitation pressure gradient (TRPG) was elevated to 92 mmHg, and the right atrium, right ventricle, and inferior vena cava were enlarged. The cardiac catheter test revealed that the mean pulmonary arterial pressure (mPAP), pulmonary capillary wedge pressure, and pulmonary vascular resistance (PVR) levels were 54 mmHg, 8 mmHg, and 13.7 Wood, respectively. The pulmonary function test revealed the percent vital capacity (%VC), FEV1.0%, and percent diffusing capacity of the lung for carbon monoxide (%DLCO) to be 117%, 82%, and 55%, respectively, thus suggesting the involvement of the lungs with impaired diffusion but not with restrictive and obstructive pulmonary disorder. Her chest X-ray and computer tomography did not reveal any pulmonary complications (Figure 1). She was diagnosed with group I PAH according to the Nice classification of PH. Serological analysis revealed antinuclear antibody (ANA) to be negative; however, the centriole pattern of staining was observed with high titer (1:640) using indirect immunofluorescence (Figure 2). Then, she was introduced to our hospital. The patient also manifested DUs, nailfold bleeding, telangiectasia (Figure 3), and Raynaud’s phenomenon but no skin sclerosis when she visited us. She has never noticed her digital sclerosis. Based on the 2013 classification criteria for SSc by the American College of Rheumatology/European League against Rheumatism, the patient was subsequently diagnosed with SSc [16] (Table 1). She was initially treated with oral vasodilators and diuretics. Beraprost (120 μg/day) and riociguat (1.5 mg/day) as vasodilators were prescribed and azosemide (60 mg/day), spironolactone (25 mg/day), and tolvaptan (3.75 mg/day) as diuretics were also prescribed in order. As edema of the lower limbs worsened immediately after macitentan was started, its use was discontinued. Dyspnea was not completely improved with beraprost and riociguat. Although we considered continuous intravenous infusion of epoprostenol as an additional therapy, the patient refused because of issues concerning aesthetics and quality of life. Therefore, we discussed with cardiologists and
suggested the use of immunosuppressive therapy, which might be effective owing to the positivity of the anticentriole antibody, a unique immunological abnormality strongly associated with SSc-PAH. Moderate doses of prednisolone (PSL; 30 mg/day) and intravenous cyclophosphamide (IVCY; 500 mg every four weeks) were initiated. After two months, these immunosuppressive therapies and vasodilators improved mPAP from 47 to 33 mmHg, 6-minute walk distance (6MWD) from 418 to 480 m, and PVR from 8.7 to 6.0 Wood. Interestingly, the anticentriole antibody also disappeared and was not detected 16 months with a slight decrease of immunoglobulin G (IgG) after the treatment. After 10 times IVCY, azathioprine (50 mg/day) was started, and PSL was gradually decreased and maintained at 5 mg/day. To achieve further improvement, a new vasodilator selexipag was added and increased up to 2 mg/day in addition to riociguat (7.5 mg/day) and beraprost (360 mg/day). PAH has been well controlled using these treatments (Figure 4).

3. Discussion

PAH is one of the most severe complications of SSc. Approximately, 10% of all patients with SSc experience PAH [17]. The associated PAHs in SSc, systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), and rheumatoid arthritis (RA) are 68%, 19%, 9%, and 5%, respectively [18]. Primary Sjögren syndrome (SS) has a very low prevalence of PAH [19]. SSc-PAH has a worse prognosis compared with other CTD-PAH, partially because the PAH of SLE, MCTD, SS, and RA were improved with the administration of immunosuppressive drugs (cyclophosphamide, prednisolone, azathioprine, and mycophenolate mofetil) [18–23]. Therefore, except for cases of progressive skin and pulmonary fibrosis, we generally do not use immunosuppressive therapies for patients with SSc [24].

Centrosome plays an important role in dividing cells with the mitotic spindle during cell cycle. It is usually located near the nucleus and moves to the bipolar of the cells after its replication during cell division. This means that the centrioles are one of the components of the centrosome located in the cytoplasm. We can detect the anticentriole antibody by the examination of antinuclear antibodies; however, it is not the antinuclear antibody but the anticytoplasmic antibody [25]. Centrosome is composed of centrioles and proteins termed the pericentriolar material (PCM) and is responsible for microtubule nucleation and anchoring [25]. Some centrosomal proteins have autoreactivities such as pericentriolar material 1 (PCM-1), pericentrin, ninein, and Cep250. Antibodies for those proteins were identified from autoimmune disease patients and postinfectious patients [26]. There is high prevalence of centrosome antibodies in SSc among autoimmune diseases [27]. Anticentriole antibody is one of anticentrosome antibodies. Connolly et al. first identified the antibody for centriole in nonimmune rabbit sera in 1978 [28]. Since 1980, several reports have been published regarding the anticentriole antibody. In these reports, the anticentriole antibody was indicated to be related to SSc [29–33]. Recently, Hamaguchi reported that 4 of 5 patients with the anticentriole antibody in SSc develop Raynaud’s phenomenon and PAH [15]. Clinically, this autoantibody is not well recognized or elucidated as an SSc-specific antibody. Using previous PubMed reports, we investigated the characteristics of patients with positive...
Although some data were unavailable, we found 16 cases of patients with anticentriole antibody between 1982 and 2015. Based on those reports, 11 of 11 (100%) patients were female. Reynaud phenomenon, DU, and PAH were observed at high rates in 100% (14 of 14), 86% (6 of 7), and 71% (5 of 7) of cases, respectively. The anticentriole antibody was reported to be associated with SSc and 4 of 15 patients (27%) did not show any cutaneous sclerosis (Table 2) [15, 30–32, 34–37]. This ratio of patients without skin sclerosis (27%) was higher than that of all patients with SSc, because only 5%–9% of SSc were classified as SSc sine sclerosis [38–40]. In addition, the anticentriole antibody is not detected as ANA; hence, such patients without clear skin sclerosis may be missed and diagnosed with “idiopathic PAH.” When an ANA-negative patient presents with DU, Raynaud phenomenon, and/or PAH, the original image of immunofluorescence of ANA staining should be reconsidered for the presence of anticentriole antibody.

To the best of our knowledge, this is the first report of an SSc-PAH patient with anticentriole antibody, who was successfully treated. In this case, the hemodynamics of PAH were further improved and stably maintained after the induction of immunosuppressive therapies. The positivity of the anticentriole antibody in SSc is extremely highly associated with PAH among other SSc-associated autoantibodies [15]. Immunosuppressive therapies decreased the titer of the anticentriole antibody. These results indicate that the pathogenesis of SSc-PAH with the anticentriole antibody may be immune-mediated. Thus, the anticentriole antibody could be a useful biomarker to identify a subpopulation of patients with SSc-PAH.

### Table 1: Peripheral blood examination inday 20 after treatment.

| Blood test (day 20) |  |
|---------------------|-----------------|
| **Urinalysis**      |                 |
| Specific gravity    | 1.021           |
| pH                  | 6               |
| Protein             | +               |
| Blood               | –               |
| Nitrite             | –               |
| WBC                 | –               |
| Bacteria            | –               |
| CBC                 | 5,000 mL        |
| Neutrophil          | 3,000 mL        |
| Eosinophil          | 0 mL            |
| Basophil            | 0 mL            |
| Lymphocyte          | 1,800 mL        |
| Monocyte            | 200 mL          |
| RBC                 | 4.77 × 10^6 mL  |
| Hb                  | 13.5 g/dL       |
| MCV                 | 89.5 fl         |
| Pt                  | 212 × 10^3 mL   |
| **Coagulation**     |                 |
| PT                  | 18.7 sec        |
| PT-INR              | 2.34            |
| APTT                | 52.9 sec        |
| D-dimer             | 0.6 mg/mL       |
| **Infection**       |                 |
| T-SPOT              | (–)             |
| HBs Ab              | (–)             |
| HBs Ag              | (–)             |
| HCV Ab              | (–)             |
| **Biochemistry**    |                 |
| T-bil               | 1.6 mg/dL       |
| D-bil               | 0.1 mg/dL       |
| ALP                 | 72 U/L          |
| γ-GTP               | 33 U/L          |
| AST                 | 35 U/L          |
| ALT                 | 34 U/L          |
| LDH                 | 297 U/L         |
| BUN                 | 10 mg/dL        |
| Cre                 | 0.55 mg/dL      |
| UA                  | 4.4 mg/dL       |
| TP                  | 6.4 g/dL        |
| Alb                 | 4 g/dL          |
| Pre-Alb             | 15 mg/dL        |
| Na                  | 142 mEq/L       |
| K                   | 3.7 mEq/L       |
| Cl                  | 107 mEq/L       |
| Ca                  | 8.4 mg/dL       |
| IP                  | 3.6 mg/dL       |
| TG                  | 101 mg/dL       |
| TC                  | 122 mg/dL       |
| LDL-C               | 69 mg/dL        |
| CPK                 | 112 U/L         |
| CK-MB               | 21 U/L          |
| Glucose             | 98 mg/dL        |
| Hb-A1c (NGSP)       | 6.2%            |
| CRP                 | 0.07 mg/dL      |
| Hp                  | ≤3.0 mg/dL      |
| Ferritin            | 69.8 ng/mL      |
| **Endocrine**       |                 |
| FT4                 | 1.17 ng/dL      |

| TSH                  | 6.33 mgIU/mL    |
| FT3                  | 2.69 pg/mL      |
| BNP                  | 432.1 pg/mL     |

| **Immune system**    |                 |
| IgG                 | 1001 mg/dL      |
| IgA                 | 228 mg/dL       |
| IgM                 | 94 mg/dL        |
| ANA                 | ≤40             |
| C3                  | 90 mg/dL        |
| C4                  | 21.8 mg/dL      |
| CH50                | 46.9 U/mL       |
| Anti-dsDNA Ab       | ≤10 U/mL        |
| Anti-RNP Ab         | ≤5.0 U/mL       |
| Anti-Sm Ab          | ≤5.0 U/mL       |
| Anti-SS-A/Ro Ab     | ≤5.0 U/mL       |
| Anti-SS-B/La Ab     | ≤5.0 U/mL       |
| Anti-Scl 70 Ab      | ≤5.0 U/mL       |
| Anti-centromere Ab  | ≤5.0 U/mL       |
| Anti-CLβ2GPI Ab     | ≤1.3 U/mL       |
| Anti-CALG Ab        | ≤1.0 U/mL       |
| iLAC                | ≤1.0 U/mL       |
| PR3-ANCA            | ≤1.0 U/mL       |
| MOPO-ANCA           | ≤1.0 U/mL       |
| RF                  | ≤5.0 U/mL       |
| Anti-CCP Ab         | ≤0.5 U/mL       |
| Anti-ARS Ab         | 10 U/mL         |
| Anti-RNA polymerase III Ab | 15.2 |
In mitotic phase, centrioles at poles of mitotic spindles were stained like 2 dots. Anticentriole antibody was detected in 1:640 by a commercial examination. The staining disappeared completely after the treatment (no data shown).

Abbreviations

IVCY: Intravenous cyclophosphamide  
PSL: Prednisolone  
BNP: Brain natriuretic peptide  
IgG: Immunoglobulin G  
Ab: Antibody  
6MWD: 6-minute walk distance  
TRPG: Transtricuspid pressure gradient  
mPAP: Mean pulmonary arterial pressure  
CO: Cardiac output  
PVR: Pulmonary vascular resistance.

Consent

The authors obtained informed consent from the patient.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank the staff of the Department of Hematology and Rheumatology, Tohoku University, for helpful discussion.
References

[1] Y. Allanore, R. Simms, O. Distler et al., “Systemic sclerosis,” Nature Reviews Disease Primers, vol. 1, p. 15002, 2015.

[2] C. P. Denton and D. Khanna, “Systemic sclerosis,” The Lancet, vol. 390, no. 10103, pp. 1685–1699, 2017.

[3] O. Kowal-Bielecka, J. Fransen, J. Avouac et al., “Update of EULAR recommendations for the treatment of systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1327–1339, 2017.

[4] P. M. Hassoun, “Therapies for scleroderma-related pulmonary arterial hypertension,” Expert Review of Respiratory Medicine, vol. 3, no. 2, pp. 187–196, 2009.

[5] O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert, “Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension,” Chest, vol. 130, no. 1, pp. 182–189, 2006.

[6] N. F. Chaisson and P. M. Hassoun, “Systemic sclerosis-associated pulmonary arterial hypertension,” Chest, vol. 144, no. 4, pp. 1346–1356, 2013.

[7] USNLo Medicine, “Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SC-PAH),” 2019, https://ClinicalTrials.gov/show/NCT01086540.

[8] USNLo Medicine, “A therapeutic open label study of tocilizumab in the treatment of pulmonary arterial hypertension (TRANSFORM-UK),” 2018, https://clinicaltrials.gov/show/NCT02676947.

[9] USNLo Medicine, “Dimethyl fumarate (DMF) in systemic sclerosis-associated pulmonary arterial hypertension,” 2019, https://ClinicalTrials.gov/show/NCT02981082.

[10] E. Sugawara, M. Kato, T. Sato et al., “Diversity of borderline pulmonary arterial pressure associated with systemic sclerosis: 3 case series,” Modern Rheumatology Case Reports, vol. 1, no. 1, pp. 9–14, 2017.

[11] Y. Furuya, T. Satoh, and M. Kuwana, “Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension,” International Journal of Rheumatology, vol. 2010, Article ID 720305, 8 pages, 2010.

[12] Y. Hamaguchi. “Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis,” The Journal of Dermatology, vol. 37, no. 1, pp. 42–53, 2010.

[13] R. T. Domsic, “Scleroderma,” Current Opinion in Rheumatology, vol. 26, no. 6, pp. 646–652, 2014.

[14] C. Liaskos, E. Marou, T. Simopoulou et al., “Disease-related autoantibody profile in patients with systemic sclerosis,” Autoimmunity, vol. 50, no. 7, pp. 414–421, 2017.

[15] Y. Hamaguchi, T. Matsushita, M. Hasegawa et al., “High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies,” Modern Rheumatology, vol. 25, no. 5, pp. 798–801, 2015.

[16] F. van den Hoogen, D. Khanna, J. Fransen et al., “2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 72, no. 11, pp. 1747–1755, 2013.

[17] R. Condiffe and L. S. Howard, “Connective tissue disease-associated pulmonary arterial hypertension,” F1000Prime Reports, vol. 7, no. 6, 2015.

[18] L. Chung, J. Liu, L. Parsons et al., “Characterization of connective tissue disease-associated pulmonary arterial hypertension from Reveal,” Chest, vol. 138, no. 6, pp. 1383–1394, 2010.

[19] D. Launay, E. Hachulla, P.-Y. Hatron, X. Jais, G. Simonneau, and M. Humbert, “Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome,” Medicine, vol. 86, no. 5, pp. 299–315, 2007.

[20] J. Zhao, Q. Wang, Y. Liu et al., “Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China,” International Journal of Cardiology, vol. 236, pp. 432–437, 2017.

[21] H. Yasuoka, Y. Shirai, Y. Tamura, T. Takeuchi, and M. Kuwana, “Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease,” Circulation Journal, vol. 82, no. 2, pp. 546–554, 2018.

[22] X. Jais, D. Launay, A. Yaici et al., “Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases,” Arthritis & Rheumatism, vol. 58, no. 2, pp. 521–531, 2008.

[23] S. Miyamiichi-Yamamoto, Y. Fukushima, K. Sugimura et al., “Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease,” Circulation Journal, vol. 75, no. 11, pp. 2688–2674, 2011.

[24] J. Konna, T. Kotani, T. Shoda et al., “Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: a retrospective study,” Modern Rheumatology, vol. 28, no. 6, pp. 1009–1015, 2018.

[25] C. L. Rieder, S. Faruki, and A. Khodjakov, “The centrosome in vertebrates: more than a microtubule-organizing center,” Trends in Cell Biology, vol. 11, no. 10, pp. 413–419, 2001.

[26] G. J. Mack, J. Rees, O. Sandblom, R. Balczon, M. J. Fritzler, and J. B. Rattner, “Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome,” Arthritis & Rheumatism, vol. 41, no. 3, pp. 551–558, 1998.

[27] I. Gavanescu, D. Vazquez-Abad, J. McCauley, J.-L. Senecal, and S. Dosskey, “Centrosome proteins: a major class of autoantigens in scleroderma,” Journal of Clinical Immunology, vol. 19, no. 3, pp. 166–171, 1999.

[28] J. A. Connolly and V. I. Kalnins, “Visualization of centrioles and basal bodies by fluorescent staining with nonimmune rabbit sera,” The Journal of Cell Biology, vol. 79, no. 2, pp. 526–532, 1978.

[29] S. Brenner, S. Pepper, and S. Berns, “Autoantibodies in human serum selectivity bind to the centriole region in cultured cells,” Journal of Cell Biology, vol. 87, p. 240, 1980.

[30] T. G. Osborn, N. J. Patel, S. C. Ross, and N. E. Bauer, “Antinuclear antibody staining only centrioles in a patient with scleroderma,” New England Journal of Medicine, vol. 307, no. 4, pp. 253–254, 1982.

[31] D. L. Tuffanelli, F. McKeon, D. M. Kleinsmith, T. K. Burnham, and M. Kirschner, “Anticentromere and anticientrobody antibodies in the scleroderma spectrum,” Archives of Dermatology, vol. 119, no. 7, pp. 560–566, 1983.

[32] Y. Moroi, I. Murata, A. Takeuchi, N. Kamatani, K. Tanimoto, and R. Yokohari, “Human anticentriole autoantibody in patients with scleroderma and Raynaud’s phenomenon,” Arthritis & Rheumatism, vol. 7, no. 6, pp. 1383–1394, 2010.

[33] J. B. Rattner, L. Martin, D. M. Waismian, S. A. Johnstone, and M. J. Fritzler, “Autoantibodies to the centrosome (centriole) react with determinants present in the glycolytic enzyme enolase,” Journal of Immunology, vol. 146, no. 7, pp. 2341–2344, 1991.
[34] D. Tuffanelli, "Persistant anti-kinetochore (centromere) and anti-centriole antibodies in scleroderma and Raynaud’s disease," *Clinical Research Journal*, vol. 30, no. 2, p. 612A, 1982.

[35] I. Hayakawa, S. Sato, M. Hasegawa, T. Echigo, and K. Takehara, "A case of scleroderma spectrum disorder with antcentriole antibody and pulmonary hypertension," *Clinical Rheumatology*, vol. 23, no. 3, pp. 266–268, 2004.

[36] S. Sato, M. Fujimoto, H. Ihn, and K. Takehara, "Antibodies to centromere and centriole in scleroderma spectrum disorders," *Dermatologia*, vol. 189, no. 1, pp. 23–26, 1994.

[37] T. G. Osborn, J. S. Ryerse, N. E. Bauer, J. M. Urhahn, D. Blair, and T. L. Moore, "Anticentriole antibody in a patient with progressive systemic sclerosis," *Arthritis & Rheumatism*, vol. 29, no. 1, pp. 142–146, 1986.

[38] M. Hinchcliff and J. Varga, "Systemic sclerosis/scleroderma: a treatable multisystem disease," *American Family Physician*, vol. 78, no. 8, pp. 961–968, 2008.

[39] R. G. Marangoni, L. F. Rocha, A. P. T. Del Rio, N. H. Yoshinari, J. F. Marques-Neto, and P. D. Sampaio-Barros, "Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort," *Rheumatology*, vol. 52, no. 8, pp. 1520–1524, 2013.

[40] H. Poormoghim, M. Lucas, N. Fertig, and T. A. Medsger Jr., "Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients," *Arthritis & Rheumatism*, vol. 43, no. 2, pp. 444–451, 2000.